Looks like Polaroid has been re-branded by none other than Lady Gaga. The pop-culture icon has a new vision for Polaroid—literally. Since January 2010, the Fame Monster has taken on the role as creative director for Polaroid, designing and branding their latest round of camera products. There is still Polaroid brand equity for Gaga to reclaim and reinvent as the “camera” evolves.

The new line, Polaroid Grey Label, will maintain the brand’s core values of simplicity, authenticity, and sharing, while targeting a new generation with the futuristic style of Lady Gaga. The Grey Label is coined from “greige goods” a fashion term for fabric in its purest form. The name expresses the simplicity of Polaroid and the style of Gaga.

The most intriguing product presented is the Polaroid GL20 Camera Sunglasses. The product was inspired by the idea to fuse the icon of instant photography, with the queen of fashionable eyewear. These glasses not only allow eye protection from the sun, but also have a built-in camera that takes pictures and video. The camera fits on the bridge of the nose and the display screens are just below eye level, not to interfere with one’s line of vision. Not only can you take pictures with these glasses, you can also play them back to the world as you live it.



Another Grey Label item is the Polaroid GL10 Instant Digital Camera. Don’t be deceived by the boxy, old-fashioned look. This camera prints digital images right into your hands! It comes with a modern LCD screen display, and brings back instant image printing, defining the Polaroid picture of the new age.



The final product is called the GL10 Instant Mobile Printer. It’s a mini machine for printing photos instantly from your phone or camera anywhere– at a party, in the office, in the car—and it’s small enough to put in a purse. It acts as a functional tool as well as a fashion accessory. According to Lady Gaga, “This product will revolutionize how we see photos. Your images will no longer die a death on your cell phone or digital camera.”

The Instant Mobile Printer, Instant Digital Camera and the Camera Glasses are a unique “look” at how to turn images into a fashion statement. The products are coming out this summer 2011, and there’s no question they will require a large chunk of change. However the price of a Polaroid in it’s heyday of the 90s did not detract from the allure of the brand. Hopefully the Grey Label will provide the same appeal.

Contributed by: Emily Hassell

FDA approves Edarbi to treat high blood pressure (source: FDA Press Announcement)

On Friday, February 25, 2011, The U.S. Food and Drug Administration approved Edarbi tablets (azilsartan medoxomil) to treat high blood pressure (hypertension) in adults.

Data from clinical studies showed Edarbi to be more effective in lowering 24-hour blood pressure compared with two other FDA-approved hypertension drugs, Diovan (valsartan) and Benicar (olmesartan).

“High blood pressure is often called the ‘silent killer’ because it usually has no symptoms until it causes damage to the body,” said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Drug Products in the FDA’s Center for Drug Evaluation and Research. “High blood pressure remains inadequately controlled in many people diagnosed with the condition, so having a variety of treatment options is important.”

Edarbi will be available in 80 milligram and 40 mg doses, with the recommended dose set at 80 mg once daily. The 40 mg dose will be available for patients who are treated with high-dose diuretics taken to reduce salt in the body.

Blood pressure is the force of blood pushing against the walls of the arteries as the heart pumps. If blood pressure rises and stays high over time, it can damage the body in many ways. Nearly 1 in 3 adults in the United States has high blood pressure, which increases the risks of stroke, heart failure, heart attack, kidney failure, and death.

Edarbi is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone.

Adverse reactions reported by patients taking Edarbi in clinical trials were similar to those reported by those taking an inactive drug (placebo).

Edarbi has a boxed warning that says the use of the drug should be avoided in pregnant women because use of the drug during the second or third trimester can cause injury and even death in the developing fetus. If a woman becomes pregnant while using the drug, it should be discontinued as soon as possible.

Edarbi is made by Takeda Pharmaceutical North America of Deerfield, Ill.

For more information on pharmaceutical naming, branding, research or submission documents, please contact Vince Budd at Addison Whitney via email or phone 704.697.4021.

Jonexa (hylastan) is a bacterially fermented product derived from hyaluronan that is indicated for the treatment of pain associated with OA of the knee and administered in one or two injections. Genzyme expects to launch Jonexa in select European Union markets and Hong Kong in 2010 because they believe opportunity exists in those markets for a lower cost, more convenient OA treatment option than locally available multiple injection products.

For more information about recent drug approvals or pharmaceutical branding, please contact Vince Budd at vbudd@addisonwhitney.com

Clinical Data, Inc. (NASDAQ: CLDA), today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD). Viibryd is a new molecular entity and the first and only selective serotonin reuptake inhibitor and 5HT1A receptor partial agonist. Clinical Data plans to make Viibryd available in U.S. pharmacies in the second quarter of this year.

“It is also the first drug that the Company has developed, and to have received marketing approval from the FDA on its first review is a significant milestone for Clinical Data.”

“When treating MDD, our goal is to offer treatment options that meet the individual needs of each patient,” said Stephen M. Stahl, M.D., Ph.D., Professor of Psychiatry, University of California, San Diego. “Viibryd is an important new treatment option with proven efficacy and a demonstrated safety profile.”

The mechanism of the antidepressant effect of Viibryd is not fully understood but is thought to be related to its enhancement of serotonergic activity in the central nervous system (CNS) through selective inhibition of serotonin reuptake. Viibryd is also a partial agonist at serotonergic 5HT1A receptors; however, the net result of this action on serotonergic transmission and its role in Viibryd’s antidepressant effect are unknown.

For more information about recent drug approvals or pharmaceutical branding, please contact Vince Budd at vbudd@addisonwhitney.com